Janssen Search
Search results
Pulmonary Hypertension
Pulmonary Hypertension Pulmonary Hypertension Normal Artery in Cross Section (Magnification x100) H&E stain Pulmonary Hypertension Overview PH Discovery PH Development PH Commercialization What is PAH Breathe In, Speak Out Five Things We Know About ...
Nature Research Custom Media: Heading Cancer Off at the Pass
Nature Research Custom Media: Heading Cancer Off at the Pass Jun 10, 2020 Excepteur sint occaecat cupidatat non Cupidatat nesciunt neque porrosed quia non numquam eius velit Sed quia non numquam eius m Excepteur sint occaecat cupidatat non Excepteur sint ...
New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)
Nov 14, 2023 United States Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO ® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex patients with PAD Janssen ...
Guide to Expanded Access
This first-of-its-kind Guide To Expanded Access includes country-specific information on the availability of Expanded Access (EA), also known as compassionate use or pre-approval access, for 28 European countries, as well as Canada. It also describes the ...
Robin L. Kumoluyi
ROBIN L. KUMOLUYI VICE PRESIDENT & CHIEF QUALITY OFFICER PHARMACEUTICALS JOHNSON & JOHNSON Robin L. Kumoluyi is Vice President and Chief Quality Officer, Johnson & Johnson, Pharmaceuticals. Robin also is a member of the Johnson & Johnson ...
Toon Overstijns
Toon Overstijns is the Global Commercial Strategy Leader for the Infectious Diseases & Vaccines Therapeutic Area. Toon started his career in Janssen as Area Managing Director for Janssen Central and Eastern Europe. He later served for five years as ...
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Jul 26, 2024 Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1, 2, 3, 4 In the MARIPOSA-2 study, ...
One Size Fits Not: The "E's" of Accessible Transformational Medicines for Those Living with Rare Diseases
One Size Fits Not: The "E's" of Accessible Transformational Medicines for Those Living with Rare Diseases Did you know that approximately 300 million people worldwide are living with one of the 6,000+ rare diseases, most of which have no ...
Focused on Hepatitis C Treatment & Prevention
Article Type: Infectious Diseases & Vaccines Hepatitis B Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is, like hepatitis C (HCV), a major global health problem and significant burden on those ...
Partner with the Janssen Prevention Center
Article Type: Disease Interception Accelerator Partner with the Janssen Prevention Center The Janssen Prevention Center (JPC) is a research group within Janssen. Launched at the start of 2015, the center will explore new approaches to disease prevention ...